Details of the Drug Combinations

General Information of This Drug (ID: DMIK6C9)

Drug Name

Zibotentan DMIK6C9

Synonyms

ZD4054; ZD-4054; ZD4054, Zibotentan; Zibotentan (JAN/INN); Trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid; N-(3-methoxy-5-methyl-pyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Discontinued in Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + Zibotentan	DC18SUA	Docetaxel	Prostate Cancer	[2]
Zibotentan + Pemetrexed	DCC8EAA	Pemetrexed	Non Small Cell Lung Cancer	[3]
Dapagliflozin + Zibotentan	DC8NX8F	Dapagliflozin	Chronic Kidney Disease	[4]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3539).
2	ClinicalTrials.gov (NCT00314782) Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
3	ClinicalTrials.gov (NCT00745875) ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
4	ClinicalTrials.gov (NCT04724837) Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)